3-(4-benzyloxyphenyl)-2,2-dimethylpropionic acid ethyl ester | 1207604-13-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-benzyloxyphenyl)-2,2-dimethylpropionic acid ethyl ester
• 英文别名: ethyl 3-(4-(benzyloxy)phenyl)-2,2-dimethylpropanoate；3-(4-Benzyloxy-phenyl)-2,2-dimethyl-propionic acid ethyl ester；ethyl 2,2-dimethyl-3-(4-phenylmethoxyphenyl)propanoate
• CAS: 1207604-13-4
• 化学式: C₂₀H₂₄O₃
• 分子量: 312.409
• InChiKey: XDUQEYYOSQERNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-benzyloxyphenyl)-2,2-dimethylpropionic acid ethyl ester 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙酸乙酯 为溶剂， 反应 12.0h， 以93%的产率得到3-(4-hydroxyphenyl)-2,2-dimethylpropionic acid ethyl ester
  参考文献：
  名称：

  Design, Synthesis, and Docking Studies of Novel Benzimidazoles for the Treatment of Metabolic Syndrome

  摘要：

  In addition to lowering blood pressure, telmisartan, an angiotensin (AT,) receptor blocker, has recently been shown to exert pleiotropic effects as a partial agonist of nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma). On the basis of these findings and docking pose similarity between telmisartan and rosiglitazone in PPAR gamma active site, two classes of benzimidazole derivatives were designed and synthesized as dual PPAR gamma agonist/angiotensin II antagonists for the possible treatment of metabolic syndrome. Compound 4, a bisbenzimidazole derivative showed the best affinity for the AT, receptor with a K-i = 13.4 nM, but it was devoid of PPAR gamma activity. On the other hand 9, a monobenzimidazole derivative, showed the highest activity in PPAR gamma transactivation assay (69% activation) with no affinity for the AT(1) receptor. Docking studies lead to the designing of a molecule with dual activity, 10, with moderate PPAR gamma activity (29%) and affinity for the AT(1) receptor (K-i = 2.5 mu M).

  DOI：

  10.1021/jm901272d
• 作为产物：
  描述：

  3-(4-benzyloxyphenyl)-3-hydroxy-2,2-dimethylpropionic acid ethyl ester 在 三乙基硅烷 、 三氟化硼乙醚 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 2.0h， 以94%的产率得到3-(4-benzyloxyphenyl)-2,2-dimethylpropionic acid ethyl ester
  参考文献：
  名称：

  [EN] THIOARYL DERIVATIVES AS GPR120 AGONISTS
  [FR] DÉRIVÉS DE THIOARYLE À TITRE D'AGONISTES DE GPR120

  摘要：

  本发明涉及规范中定义的Formula 1的硫代芳基衍生物，一种制备该衍生物的方法，包含该衍生物的药物组合物以及其用途。根据本发明，Formula 1的硫代芳基衍生物促进胃肠道中GLP-1的形成，并通过抗炎作用改善巨噬细胞、胰腺细胞等的胰岛素抵抗，因此可以有效用于预防或治疗糖尿病、糖尿病并发症、炎症、肥胖、非酒精性脂肪肝、脂肪性肝炎或骨质疏松症。

  公开号：

  WO2014069963A1

文献信息

• THIOARYL DERIVATIVES AS GPR120 AGONISTS
  申请人：LG LIFE SCIENCES LTD.

  公开号：US20150291527A1

  公开（公告）日：2015-10-15

  The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.

  本发明涉及公式1中定义的硫代芳基衍生物，其制备方法，包含其的药物组合物以及使用方法。本发明中的公式1中的硫代芳基衍生物能够促进胃肠道中的GLP-1形成，并通过抗炎作用改善巨噬细胞、胰腺细胞等的胰岛素抵抗力，因此可以有效用于预防或治疗糖尿病、糖尿病并发症、炎症、肥胖症、非酒精性脂肪肝、脂肪性肝炎或骨质疏松症。
• Thioaryl derivatives as GPR120 agonists
  申请人：LG LIFE SCIENCES LTD.

  公开号：US09447044B2

  公开（公告）日：2016-09-20

  The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.

  本发明涉及公式1中定义的硫代芳基衍生物，其制备方法，包括其的药物组合物以及使用方法。本发明的公式1中的硫代芳基衍生物可以促进胃肠道中的GLP-1形成，并由于其抗炎作用改善巨噬细胞、胰腺细胞等的胰岛素抵抗力，因此可以有效地用于预防或治疗糖尿病、糖尿病并发症、炎症、肥胖、非酒精性脂肪肝、脂肪性肝炎或骨质疏松症。
• US9447044B2
  申请人：——

  公开号：US9447044B2

  公开（公告）日：2016-09-20